Tools4Patient (T4P) takes an academic approach to the commercialization of technology centered around the optimization and acceleration of therapeutic drug development programs. The first product launched is Placebell©™, which through a variety of data capture sources and analyses characterizes the individual placebo response in subjects and patients enrolled in clinical trials.

Founded in 2013 and based in Gosselies, Belgium, Tools4Patient is a privately- held innovative company engaged in creating analytical tools with both research and clinical applications. The company strives to improve patient quality of life by supporting physicians’ and pharmaceutical/biotechnology companies’ efforts in identifying the right therapeutic for each individual patient.

The company is taking full advantage of its founders’ extensive expertise and experience in drug development. Their experience and that of our extensive professional network of advisors, consultants, and collaborators provide T4P’s core scientists and operational groups with the efficiency, practical know-how, and knowledge required to achieve the company’s objectives. Patients, however, are the essential link in the development of future treatments; T4P could not continue to develop new technologies without them. Therefore, care is taken to ensure that patients are involved at every stage of development, listening constantly to their needs and seeing them as critical stakeholders in the clinical research process.

 

Mission & Vision

  • To achieve innovation by challenging the dogma of drug development and disrupting the status quo
  • By building on the diverse nature of the core team with complimentary expert advisors, consultants, and collaborators advancements will occur with maximum speed and minimal drag
  • Every decision is made with the highest ethics and integrity constantly keeping in mind patients’ well-being
  • To communicate openly and honestly with patients, sponsors, regulatory bodies, and investors

 

Executives Management Board

portrait Dominique Demolle, CEO

Dominique Demolle

CEO

Dominique Demolle

CEO

Dominique Demolle serves as Chief Executive Officer of Tools4Patient since its inception in 2013.

Dr. Demolle holds a Ph.D. in Biochemistry from the University of Brussels. She joined the Clinical Research Group of GD Searle Belgium where she was in charge of early phase compound development. She has held positions with increasing leadership responsibilities at Eli Lilly and Company beginning at the Lilly Indianapolis Clinical Research Unit in the US and the European Operational Staff management in Louvain-la-Neuve where she ultimately became the Associate Director of Global Early Phase Operations. In 2007 she co-founded Aepodia, a consultancy clinical research organization where she was CEO. 

portrait Alvaro Pereira, CSO

Alvaro Pereira

CSO

Alvaro Pereira

CSO

Alvaro Pereira holds the position of Chief Scientific Officer at Tools4Patient since its inception in 2013. Dr. Pereira holds a Ph.D. in Biochemistry from the University of Brussels. Dr. Pereira continued his academic research as a Research Fellow in the Bioorganic Chemistry and Neurophysiopathology Departments at the same institution. He began his industrial career at Eli Lilly and Company in the Clinical Pharmacology Department. Throughout his industrial career he has worked in clinical pharmacology with increasing responsibilities from individual Phase I studies through managing entire early stage development programs (including proof of concept Phase IIa studies) for novel CNS agents. In 2007 he joined Aepodia, a consultancy clinical research organization where he ran the early stage development section which was comprised of all studies from first-in-human through Phase IIb proof of concept including biomarker validation/development in a variety of different therapeutic areas.

portrait Chantal Gossuin, COO

Chantal Gossuin

COO

Chantal Gossuin

COO

Chantal Gossuin works as Chief Operating Officer at Tools4Patient since its inception in 2013. Ms. Gossuin holds a Master’s degree in Industrial Pharmacy from the University of Brussels. Ms. Gossuin began her industrial career in the Quality Control Department at Eli Lilly and Company, Fegersheim. Thereafter, she held positions with increasing responsibility at Lilly in the Clinical Trial Material Department where she was ultimately promoted to Team Leader. She then moved to UCB as Project Manager, Drug Product Management and Industrialization Department. In 2008 she became Clinical Project Leader at Aepodia, a consultancy clinical research organization.

Board of Directors

portrait Dominique Demolle, CEO

Dominique Demolle

CEO

Dominique Demolle

CEO

Dominique Demolle has served as Chief Executive Officer of Tools4Patient since its inception in 2013.

Dr. Demolle holds a Ph.D. in Biochemistry from the University of Brussels. She joined the Clinical Research Group of GD Searle Belgium where she was in charge of early phase compound development. She has held positions with increasing leadership responsibilities at Eli Lilly and Company beginning at the Lilly Indianapolis Clinical Research Unit in the US and the European Operational Staff management in Louvain-la-Neuve where she ultimately became the Associate Director of Global Early Phase Operations. In 2007 she co-founded Aepodia, a consultancy clinical research organization where she was CEO.

portrait Marc Ponet

Marc Ponet

Marc Ponet

Mr. Ponnet holds a B.S. in biotechnology from University College of Ghent and a B.S. in tax science from EHSAL Management School. He started his career at Général de Banque and then founded B-Connected, a call center based in Brussels and employing about 300 people. He also owns Nixxis, a company dedicated to the development of software for call- and contact centers which is also located in Brussels. His entrepreneurial activities led him to invest in several technology companies as well as a number of real estate projects. His broad business background has established him as a successful entrepreneur.

portrait Marc Nolet de Brauwere

Marc Nolet de Brauwere

Marc Nolet de Brauwere

Marc Nolet de Brauwere was appointed CEO of PhysIOL in 1997 when he took over the company. He previously held different positions at Petrofina S.A. in the US and as an associate at McKinsey. In addition to his leadership role at PhysiOL, he is currently Chairman of the board at Endo Tools Therapeutics and an Independent Director in several other Companies' Boards. Marc holds a Master’s degree in Civil Mining Engineering from the Université Catholique de Louvain, Belgium and a Master’s degree in Industrial Management from the Katholieke Universiteit Leuven.

portrait Yves Vandekerkchove

Yves Vandekerkchove

Yves Vandekerkchove

Yves Vandekerkchove is one of the founders of 4Reliance, a corporate finance firm located in Brussels and Paris. He holds degrees in Law and Business Administration (Université Catholique de Louvain & University of Wales) and acquired international corporate finance experience working in Peru and India (Mumbai). Yves is passionate about true entrepreneurship. He enjoys building successful corporate strategies, determining the right market positioning and increasing the intrinsic value of companies. His commitment brought him to build long-term relationships with entrepreneurs and his transaction counterparts. He is director in several other Companies' Boards.

portrait John Hall

John Hall

John Hall

Dr. Hall holds a Ph.D. in pharmacology from Aston University, U.K. He has over 45 years of international experience in the biotechnology, pharmaceutical, and contract research organization industries at senior executive level. In 2008 he co-founded Leader Partners Ltd., a boutique consulting firm specialized in the evaluation and development of contract service businesses on behalf of international private equity organizations. Previously, Dr. Hall was President, European Operations at AAIPharma Inc. where he was responsible for the creation and expansion of preclinical and clinical services across Europe and South Africa. He also served as Senior Vice President of Corporate Development for Quintiles Transnational Corp. and in senior R&D positions in GD Searle, Monsanto, Inveresk Research and Roche. He has been an Honorary Lecturer in Management Studies at St. Andrew’s University and an invited speaker and chairman at conferences in the United States, Europe and Asia. He holds a number of non-executive board positions in Europe and the Middle East.

Scientific Advisory Board

portrait Alvaro Pereira, CSO

Alvaro Pereira

CSO

Alvaro Pereira

CSO

Alvaro Pereira holds the position of Chief Scientific Officer at Tools4Patient since its inception in 2013. Dr. Pereira holds a Ph.D. in Biochemistry from the University of Brussels. Dr. Pereira continued his academic research as a Research Fellow in the Bioorganic Chemistry and Neurophysiopathology Departments at the same institution. He began his industrial career at Eli Lilly and Company in the Clinical Pharmacology Department. Throughout his industrial career he has worked in clinical pharmacology with increasing responsibilities from individual Phase I studies through managing entire early stage development programs (including proof of concept Phase IIa studies) for novel CNS agents. In 2007 he joined Aepodia, a consultancy clinical research organization where he ran the early stage development section which was comprised of all studies from first-in-human through Phase IIb proof of concept including biomarker validation/development in a variety of different therapeutic areas.

portrait Jean Stephenne

Jean Stephenne

Jean Stephenne

Jean Stephenne holds an MSc in Chemistry and Bioindustries from Gembloux/Liège University and obtained an MBA in Management from Louvain-la-Neuve University. Mr. Stephenne joined SmithKline-RIT., where he held positions with increasing leadership responsibilities in the Vaccines Division and was ultimately chosen to become President and General Manager of GlaxoSmithKline Biologicals. During his nearly 40 years at GSK, he steered the company through a series of mergers and acquisitions to create one of the leading global vaccine companies. He retired from GSK in 2012. Today many companies take advantage of Mr. Stephenne’s remarkable industrial experience. His experience has also led him to preside over the Walloon Union of Companies from 1997 to 2000 where he currently still serves on the Board of Administrators.

portrait Marc Buyse

Marc Buyse

Marc Buyse

Dr. Buyse holds degrees in engineering and statistics from the Brussels University, management from the Cranfield School of Management and a doctorate in biostatistics from Harvard University. Dr. Buyse is a founder and Chairman of IDDI (Biostatistical and eClinical Services Company), and Associate Professor of Biostatistics at the Hasselt University. Dr. Buyse was the recipient of several research fellowships in Belgium, the US, and Japan. He is the past President of the International Society for Clinical Biostatistics, President of the Quetelet Society, and Fellow of the Society for Clinical Trials. He worked at the EORTC (European Organization for Research and Treatment of Cancer) in Brussels and at the Dana Farber Cancer Institute in Boston prior to founding IDDI in 1991. 

portrait Sanjay  Dube

Sanjay Dube

Sanjay Dube

Dr. Dube holds an MD in Psychiatry from the King George’s Medical College. Dr. Dube’s clinical and academic career started at the Lafayette Clinic (Wayne State University) in Detroit and was on staff there for 10 years. Dr. Dube then moved to the Western Psychiatric Institute and Clinic at the University of Pittsburgh as Adjunct Associate Professor of Psychiatry. In 2001 he joined the Indiana University School of Medicine as Adjunct Clinical Professor of Psychiatry. He has received several teaching awards including the prestigious Nancy Roeske Award from the American Psychiatric Association and the Excellence in Teaching Award from the Association of Academic Psychiatry. In 2014, Dr. Dube was appointed as a Consulting Associate Professor of Psychiatry at the Stanford University School of Medicine and Behavioral Sciences and continues to hold adjunct appointments at IU School of Medicine and the University of Pittsburgh. Dr Dube’s industrial carrier started at Eli Lilly and Company in 2001 as Medical Director in the late stage division and finishing as Senior Medical Fellow.  Dr. Dube contributed to the development of several novel compounds for the treatment of severe mental illnesses. Additionally he has lead the Phase 2 program for chronic pain medications at Theravance Biopharma and recently he has joined Avanir where is responsible for the CNS pipeline as Vice President, Clinical Development. Dr Dube is widely published and is a member of several international medical organizations.

portrait John Bloom

John Bloom

John Bloom

John C. Bloom holds a B.S. degree in biology from the University of Pittsburgh and doctorates in veterinary medicine and experimental hematology from the University of Pennsylvania. He completed his postdoctoral training at Jefferson Medical College in hematology/oncology and served on the faculty of the University of Pennsylvania School of Veterinary Medicine as Chief, Clinical Laboratory Medicine, before joining Smith Kline & French Laboratories as Associate Director of Pathology. He later joined Lilly Research Laboratories as Head, Clinical Pathology in the Toxicology Division, and subsequently moved to the Medical Division, where he established the departments of Clinical Laboratory Medicine, Experimental Medicine and Clinical Diagnostic Services. As Executive Director and Distinguished Medical Fellow, Diagnostic and Experimental Medicine, he was responsible for routine laboratory, ECG, imaging and specimen banking support for global clinical development; and novel clinical biomarker discovery, validation and application in the Division of Translational Medicine and Pharmacogenomics. Upon his retirement from Lilly in 2009 he established Bloom Consulting Services, LLC and was appointed Special Consultant, Office of the Center Director, FDA.  Dr. Bloom serves on several Scientific Advisory Committees for pharmaceutical, diagnostic and pharmaceutical services companies and holds adjunct academic appointments at the University of Pennsylvania and Purdue University.

portrait

Didier Bouhassira

Didier Bouhassira

Dr Didier Bouhassira (MD, PhD) has been trained in neurology and neurophysiology in Paris. He has been involved in both basic and clinical research on pain and is currently Director of Research at the National Institut for Health and Medical Research (INSERM). He is associate attending neurologist in the Pain Clinic at Ambroise Paré hospital in Boulogne-Billancourt and director of the laboratory of "Pathophysiology and Clinical Pharmacology of Pain" (INSERM U-987).

Didier Bouhassira is an active member of several international associations or societies and is the immediate past president of the French Pain Sociedty. He is field editor for the European Journal of Pain and associate editor for several scientific journals including Pain. He has co-authored over 180 articles in peer reviewed journals and has written a number of book chapters devoted to the pharmacology and pathophysiology of pain.

Commitment

As the name Tools4Patient implies, our commitment is to work with and for patients, focusing on their individual traits and circumstances. This commitment underpins the creation of Tools4Patient and is the common goal of all its employees and collaborators. The ultimate goal of Tools4Patient is to make a discernible difference in patients’ lives, in the development of meaningful therapeutics, and the entire medical community.

Partners

portrait Aepodia

Aepodia

Aepodia

Aepodia specializes in the strategy and delivery of early drug and Medical Device development and provides scientific consultancy as well as operational support across various indications including but not limited to CNS, Endocrinology, Metabolic Disease, and Oncology. 

The experienced clinical trial team can implement, manage and conduct clinical trials by offering “ad hoc” or “full service” support to complement the sponsor’s in-house team (e.g. Data Management, Regulatory Strategy, Study design, Project Coordination, Monitoring, Competent Authority Submission, Site Selection/Assessment/Management, Medical Writing, etc.).  

portrait DNalytics

DNalytics

DNalytics

DNalytics’ R&D consultancy unit offers scientific innovation for data analysis in the field of personalized medicine to all players in clinical research: pharmaceutical and biotech companies, as well as academic and other private laboratories.  

Their main strength is designing predictive solutions (diagnostic, prognostic, treatment response prediction, etc.) and the identification of the necessary biomarkers to enable them. 

portrait CIC

CIC

CIC

The “Clinical Investigation Centre” in the Clermont-Ferrand teaching hospital is the referent in Pain Translational Medicine for Inserm, the French Institute of Health and Medical Research. 

The unit works with many departments of the hospital including: Pain Clinic and anaesthesia services, neurology, neurosurgery, oncology, dentistry, gastroenterology.

portrait Région Wallonne – DGO6

Région Wallonne – DGO6

Région Wallonne – DGO6

The Walloon Region supports R&D companies through its Research and Technological Portal. They help companies to innovate by supporting the development of new products, processes and services, the acquisition of new technologies and strengthening their scientific and technological potential.

portrait Eureka

Eureka

Eureka

EUREKA is an intergovernmental organization?for market-driven industrial R&D. It is a decentralized network facilitating the coordination of national funding for innovation aimed at boosting productivity & competitiveness in European industries. Following a bottom-up approach with projects relating to any technological field in the civilian sector, EUREKA has been the driving force of innovation in Europe for over 25 years.

Privacy statement

We take very seriously our obligations to protect the privacy of our partners including our clients, their employees and business partners as well as that of the participants in all Clinical Trials conducted by our clients and/or ourselves.

This privacy policy has been updated to be consistent with the requirements of the EU General Data Protection Regulation and describes how we collect and use personal information.  It also explains how to obtain further information on the data we hold.

Tools4patient.SA. is registered as a Data Controller with APD (Autorité de protection des données) (Registration number 10DJZ2ZD).

How we use your information

We hold personal information where this is necessary to interact with our business partners including their employees; our clients (e.g. Sponsors); our suppliers (e.g. Clinical Investigator Sites) and any other business partners such as worldwide regulatory agencies for the purposes of agreeing or executing project contracts with them.

When business partners disclose information to us we assume that they have the necessary agreements in place with the other parties for this disclosure.

We also hold pseudonymised data information from subjects participating in clinical trials conducted by our clients or by ourselves. This supports the clinical trials data analysis. Prior to participating in a clinical trial, the subjects receive, in the informed consent document, the information regarding the collection, storage, transfer, and use of their data. Those data are always pseudonymised and in some circumstances anomimyzed.

Information that we hold

The information that we hold, related to our business partners, includes business and individual names, business addresses, business email addresses and telephone numbers. It also includes financial information necessary for the processing of payments.

We do not collect any sensitive personal data from our clients or business partners.

No sensitive personal data will be collected relating to participants in Clinical Trials with the very rare exception that it may be necessary to copy an exhibit during an audit of a trial to provide evidence of an issue.  In the rare even that this is necessary, all identifiers such as patient name or date of birth will be redacted at the point of collection leaving only the patient number visible.

How your data are stored and protected

Information may be stored electronically in our IT systems and infrastructure, or in our offices with required protection measures to limit uncontrolled access.

We will not supply personal information from a business partner to any third party without explicit permission, except as necessary to complete our contracts with this business partner or to fulfil our business or legal obligations

We will not knowingly transmit your information outside of the EEA unless necessary to perform an agreed project, for example agreed communications with a US employee of one of our business partners, agreed communication with a Regulatory Agency or in preparation for an audit of a site in a third country.

How long do we retain information

We do not collect more information than we need to fulfil our stated purposes and will not retain it for longer than is necessary to complete our agreed projects, fulfil contract terms or as required by laws or regulatory guidelines related to the project activities or general business obligations such as financial records. 

Since most of our projects relate to regulated Clinical Trial activities, it is likely that most records will be retained for many years unless we are notified by our clients that this retention is no longer necessary.  As a minimum, records of all activities, including correspondence, will be retained for at least 6 years.

We review our records annually to ensure that we are not holding unnecessary information.

Access to personal information/your rights

Tools4patient will be as open as we can be in terms of giving people access to their personal information. If we do hold information about you, we will:

  • give you a description of it
  • tell you why we are holding it;
  • tell you who it could be disclosed to; and
  • let you have a copy of the information in an intelligible form.

If we do hold information about you, you can ask us to have access to it and correct any mistakes.

You have the right to ask us not to use your personal information in the future and to remove your details from our databases and mailing lists.

We would also like to contact our clients periodically to provide general updates on information that we think may be of interest (e.g. changes in regulations) or updates on services that we offer.  If you or any of your employees wish to be removed from our mailing list for general communications, you may at any time unsubscribe directly from Tools4Patient’s newsletter through “unsubscribe option” (always available) or send a message to us at dpo@tools4patient.com and we will take immediate action.

You also have the right to ask use to erase stored information about you and we will do this unless continued storage is required as part of a contractual, legal or regulatory obligation.

All requests relating to your personal information should be sent to us in writing at our registered offices and by email to DPO@tools4patient.com.